Please assess the completion status of the following clinical trial:

Trial Title: Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Advanced (unresectable or metastatic) carcinoid tumor~* Confirmed low-grade or intermediate-grade neuroendocrine carcinoma~* Documented progression of disease within 12 months prior to randomization.~* Measurable disease determined by triphasic computer tomography (CT) scan or magnetic resonance imaging (MRI).~Exclusion criteria:~* Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoma, or small cell carcinoma.~* Hepatic artery embolization within the last 6 months or cryoablation of hepatic metastasis within 2 months of enrollment.~* Previous treatment with mammalian target of rapamycin (mTOR) inhibitors (sirolimus, temsirolimus, everolimus)~* Intolerance or hypersensitivity to octreotide, everolimus, or other rapamycins.~* Severe or uncontrolled medical conditions~* Chronic treatment with corticosteroids or other immunosuppressive agent.~* Other primary cancer within 3 years.~Other protocol-defined inclusion/exclusion criteria applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octreotide+ Everolimus (Type: EXPERIMENTAL): Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.
- Octreotide+ Placebo (Type: PLACEBO_COMPARATOR): Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).